0001062993-23-002309.txt : 20230206 0001062993-23-002309.hdr.sgml : 20230206 20230206185032 ACCESSION NUMBER: 0001062993-23-002309 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230202 FILED AS OF DATE: 20230206 DATE AS OF CHANGE: 20230206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Borges Luis CENTRAL INDEX KEY: 0001684015 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40498 FILM NUMBER: 23592104 MAIL ADDRESS: STREET 1: TWO CORPORATE DRIVE STREET 2: C/O FIVE PRIME THERAPEUTICS, INC. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Century Therapeutics, Inc. CENTRAL INDEX KEY: 0001850119 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 842040295 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 215-981-4000 MAIL ADDRESS: STREET 1: 3675 MARKET STREET CITY: PHILADELPHIA STATE: PA ZIP: 19104 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2023-02-02 0001850119 Century Therapeutics, Inc. IPSC 0001684015 Borges Luis 3675 MARKET STREET PHILADELPHIA PA 19104 0 1 0 0 Chief Scientific Officer Common Stock 2023-02-02 4 A 0 21875 0 A 21875 D Common Stock 2023-02-02 4 A 0 21875 0 A 43750 D Stock Option (right to buy) 4.64 2023-02-02 4 A 0 131250 0 A 2033-02-02 Common Stock 131250 131250 D Stock Option (right to buy) 4.64 2023-02-02 4 A 0 131250 0 A 2033-02-02 Common Stock 131250 131250 D Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock. The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer. /s/ Michael Diem, Attorney-in-Fact 2023-02-06